TNF Pharmaceuticals, Inc. (TNFA)
NASDAQ: TNFA · Real-Time Price · USD
0.1050
-0.0050 (-4.55%)
At close: Aug 13, 2025, 4:00 PM
0.0998
-0.0052 (-4.95%)
Pre-market: Aug 14, 2025, 9:25 AM EDT
TNF Pharmaceuticals Employees
TNF Pharmaceuticals had 2 employees as of December 31, 2024. The number of employees decreased by 4 or -66.67% compared to the previous year.
Employees
2
Change (1Y)
-4
Growth (1Y)
-66.67%
Revenue / Employee
n/a
Profits / Employee
-$9,048,775
Market Cap
1.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -4 | -66.67% |
| Dec 31, 2023 | 6 | -3 | -33.33% |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TNFA News
- 7 weeks ago - TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease - Business Wire
- 3 months ago - TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists - Business Wire
- 4 months ago - TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development - Business Wire
- 4 months ago - TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025 - Business Wire
- 5 months ago - TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia - Business Wire
- 5 months ago - TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 - Business Wire
- 6 months ago - TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - Business Wire
- 7 months ago - TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment - Business Wire